Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Hospira, Inc., A Pfizer Company
EIR
•Hospira, Inc., A Pfizer Company•August 16, 2013

Hospira, Inc., A Pfizer Company – FDA EIR, Aug 16, 2013

Record Details

An FDA inspection was conducted at Hospira, Inc. in McPherson, KS, from July 29 to August 16, 2013. This directed inspection focused on Drug Quality Reporting System (DQRS) and NDA-Field Alert Reports, initiated due to several priority DQRS reports received by the FDA. The primary violation identified was Hospira's failure to file seven NDA-Field Alerts for complaints involving confirmed glass particulate contamination in sterile lyophilized products between December 2012 and July 2013. This issue was highlighted as a recurring observation, having been verbally noted in the three preceding inspections regarding the requirement to file NDA-Field Alerts within three days, as stipulated by 21 CFR 314.81(b)(1)(ii). Management was engaged in discussions about this non-compliance and the implications for distributed products, though they expressed confidence in their products despite the identified reporting lapses. Additionally, the inspection reviewed numerous "Lack of Efficacy" complaints for products like Marcaine HCl w/ Dextrose and Bupivacaine Spinal Injection. While retention samples for one lot of Bupivacaine were found within specifications, the persistent high volume of these complaints was noted, prompting the firm to refer to an internal position paper on the issue. The inspection underscores the necessity for timely and accurate reporting of adverse product events to ensure patient safety and regulatory compliance.

Company
Hospira, Inc., A Pfizer Company
Inspection date
August 16, 2013
Product type
drugs
Office
Kansas City District Office
People
  • Shirley J. Berryman (Owner)
  • Zena G. Kaufman
  • Janet B. Abt (investigator)
View Company Profile

ID · 047cbead-9a67-46d5-b49e-6be9a5721673

Violation Codes1
21 CFR 314.81(b)(1)(ii)

Full citation text and observation details available on the Dashboard.

Other documents for Hospira, Inc., A Pfizer Company
  • 483 - 2026-03-10March 10, 2026
  • 483 - 2025-01-17January 17, 2025
  • 483 - 2023-06-30June 30, 2023
  • EIR - 2020-01-17January 17, 2020
  • 483 - 2020-01-17January 17, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hospira, Inc., A Pfizer Company
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.